Following reports of potential contamination with Bacillus cereus end of March 2012, manufacturer Bristol-Myers Squibb issued a voluntary precautionary recall of all batches of Viaspan®, a solution used for the preservation of kidney, liver and pancreas before transplantation. The batches in question had been produced since 4 July 2011.
The initial ECDC rapid risk assessment from start of April was updated on 18 April following new information received from the manufacturer and the UK’s Health Protection Agency (HPA) and includes recommendations for reducing the risk of infection. So far, no cases of B. cereus infection in transplanted patients have been reported. However, B. cereus can cause serious infection in immune-suppressed patients. The risk assessment was distributed to the European Commission and to national authorities responsible for organ safety.
In addition, ECDC continued monitoring measles outbreaks and influenza activities in Europe. No new measles outbreaks or clusters were detected in EU Member States while the UK outbreaks show that the number of cases is still increasing. During week 15, decreasing influenza transmission trends were reported by 14 countries, 13 of which have reported such trends for at least two consecutive weeks.
Read the full ECDC communicable disease threats report (CDTR), week 16
ECDC risk assessment Potential contamination of Viaspan® organ perfusion solution
European monthly measles monitoring, March 2012
ECDC rapid risk assessment on the measles outbreak in the Ukraine
Weekly Influenza Surveillance Overview, week 15